5-aminomethylquinoxaline-2,3-diones. Part 1: A novel class of ampa receptor antagonists.

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 1, 1998, Pages 65-70

  Auberson, Yves P ^a   Bischoff, Serge ^a   Moretti, Robert ^a,b   Schmutz, Markus ^a   Veenstra, Siem J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOMETHYLQUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; MICE; QUINOXALINES; RECEPTORS, AMPA; SEIZURES;

ANIMALIA;

EID: 0032488647     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10186-X     Document Type: Article

References (20)

1. 1. a) Choi, D.W.; Rothman, S.M Annual Rev. Neurol. 1990 13 171.
2. b) Beal, M.F. FASEB J. 1992 6 3338.
3. 2. a) Gill, R.; Lodge, D. Neuropharmacology 1994 33 1529.
4. b) Xue, D.; Huang, Z.-G.; Barnes, K.A.; Lesiuk, H.J.; Smith, K.E.; Buchan, A.M. J. Cerebr. Blood Flow Metab. 1994 74 251.
5. 3. a) Nellgard, B.; Wieloch, T. J. Cerebr. Blood Flow Metab. 1992 12 2.
6. b) Buchan, A.M.; Lesiuk, H.J.; Barnes, K.A.; Li, H.; Huang, Z.-G.; Smith, K.E.; Xue, D. Stroke 1993 24 148.
7. c) Sheardown, M.J.; Suzdak, P.D.; Nordholm, L. Eur. J. Pharmacol 1993 236 347.
8. 4. a) Namba, T.; Morimoto, K.; Sato, K.; Yamada, N.; Kuroda, S. Brain Res. 1994 638 36.
9. b) Yamaguchi, S.I.; Donevan, S.D.; Rogawski, M.A. Epilepsy Res. 1993 15 179.
10. 5. a) Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. J. Med. Chem. 1996 39 3971, and ref. cited therein.
11. b) Bigge, F.C.; Malone, T.C.; Boxer, P.A.; Nelson, C.B.; Ortwine, D.F.; Schelkun, R.M.; Retz, D.M.; Lescosky, L.J.; Boroski, S.A.; Vartanian, M.G.; Schwarz, R.D.; Campbell, G.W.; Robichaud, L.J.; Wätgen, F. J. Med. Chem. 1995 38 3270.
12. c) Lubisch, W.; Behl, B.; Hofmann, H.P. Bioorg. & Med. Chem. Letters 1996 23 2887.
13. d) Sheardown, M.J.; Meisen, E.O.; Hansen, A.J.; Jacobsen, P.; Honoré, T. Science 1990 247 571.
14. e) Turski, L.; Huth, A.; Sheardown, M.J.; Jacobsen, P.; Ottow, E. 26th Annual Meeting of the Society for Neuroscience, Washington D.C., November 16-21, 1996, poster 604.6.
15. 6. St. Clair, R.L.; Thibault, T.D. US Patent # 3992378 1976 (CA 86:89890m).
16. 3, 86%), followed by alkylation with ethyl 4-pipecolate and hydrolysis as exemplified in scheme 1 for e.g. 1a.
17. 3H]AMPA binding assay: Honoré, T.; Lauridsen, J.; Krogsgaard-Larsen, P. J. Neurochem. 1982 38 173.
18. 3H]MDL-105.519 binding assay: Baron, B.M., Siegel, B.W., Harrison, B.L., Gross, R.S., Hawes, C. and Towers, P. J. Pharmacol. Exp. Ther. 1996 279 62-68.
19. 9. a) Schmutz, M.; Portet C.; Jeker, A.; Klebs, K.; Vassout, A.; Allgeier, H.; Heckendorn, R.; Fagg, G. E.; Olpe, H.R.; van Riezen, H. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990 342 61.
20. b) Wamil, A.; Schmutz, M.; Portet, C.; Feldmann, K.F.; McLean, M.J. Eur. J. Pharmacol. 1994 277 301.